Poliovirus type 1 in working stocks of typed human rhinoviruses

Lancet

Volumn 361, Issue 9364, 2003, Pages 1187-1188

  Davies, Marc ^a   Bruce, Christine ^a   Bewley, Kevin ^a   Outlaw, Mark ^a   Mioulet, Valerie ^a   Lloyd, Graham ^a   Clegg, Christopher ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; HUMAN RHINOVIRUS; MICROBIOLOGICAL EXAMINATION; NONHUMAN; POLIOMYELITIS VIRUS 1; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEROTYPE; VIRUS TYPING; WORLD HEALTH ORGANIZATION;

EID: 0037420496     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12919-4     Document Type: Article

References (5)

1. Minor P.D. Biosafety consequences of eradication of wild-type polioviruses. Lancet. 358:2001;166-168.
2. WHO Department of Vaccines and Biologicals. WHO global action plan for laboratory containment of wild polioviruses. Document WHO/V&B/99.32. Geneva: WHO, 1999. http://www.who.int/vaccines-documents/DocsPDF99/www9956.pdf (accessed Aug 9, 2002).
3. Dove A.W., Racaniello V. The polio eradication effort: should vaccine eradication be next? Science. 227:1997;779-780.
4. Savolainen C., Blomqvist S., Mulders M.N., Hovi T. Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. J Gen Virol. 83:2002;333-340.
5. Mulders M.N., Lipskaya G.Y., van der Avoort M.G.A.M., Koopmans M.P.G., Kew O.M., van Loon A.M. Molecular epidemiology of wild poliovirus type 1 in Europe, the Middle East, and the Indian subcontinent. J Infect Dis. 171:1995;1399-1405.